Furthermore, targeting PLK1, SETD8, and facilitator of chromatin transcription (FACT) with their respective inhibitors onvasertib, UNC0379, and CBL0137 has also shown preclinical activity against MYC-amplified medulloblastoma [112,113,114]. The gene discussed is PLK1; the disease is medulloblastoma.